Patient demand for better glaucoma treatments is still on the rise. This demand has led to increased revenues for the Treatment and Therapeutics markets, according to two new reports from Transparency Market Research. The growth is expected to continue through 2028.
In 2017, the global glaucoma Therapeutics market was valued at $5,932.6 Mn USD and is expected to reach $7,659.8 Mn USD by 2026. This increase is driven by the increased prevalence of diabetic disorders, increased older adult population, combination therapies, and more.
Hospitals captured major share of the Therapeutics market in 2017 and are projected to continue to do so due to a large population preferring visiting hospitals rather than specialty clinics for treatment.
North America continues to be a leading revenue contributor to the Treatment market due to increased incidences of glaucoma and resulting need for glaucoma drugs. In 2017, North America and Europe accounted for a combined market share of 50.2%. More than $3,300 Mn USD is expected globally from glaucoma treatment by the end of 2026.
You can read more here.